Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
Key facts
- Who runs it
- Fudan University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Jan 2020
- Ended
- 31 May 2024
- Type of study
- Observational
- Treatments tested
- Fruquintinib Combined With TAS-102
- Record updated
- 3 August 2026
- Why it stopped
- The study was withdrawn before participant enrollment because the research team decided not to initiate the study after reassessing its feasibility.
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Histology-confirmed metastatic CRC (mCRC)
- Disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab
- Fruquintinib administered as salvage treatment
- Age: 18-75 years old
- Informed consent
Who cannot take part
- Drug administration stopped after less than two cycles
- Liver or kidney dysfunction, or other conditions unsuitable for chemotherapy
- Fruquintinib and/or TAS-102 administration as second-line treatment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because of its multi-target mechanism which enhances the sensitivity of the immune system and chemotherapy, aiming to further improve the survival benefits for mCRC patients. Trifluridine/tipiracil (TAS-102) is also a standard treatment for mCRC. This study aims to investigate the safety and effectiveness of the combined use of these two drugs in mCRC.
The group in the trial
- Fru plus TAS-102
mCRC patients receiveing Fruquintinib combined with TAS-102 in third- or late- line
Treatment: Fruquintinib Combined With TAS-102
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Single-center, Prospective Cohort Study of Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
- Record updated
- 3 August 2026